Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke

Thrombolytic stroke therapy with tissue plasminogen activator (tPA) is limited by risks of hemorrhagic transformation (HT). We have reported that a new 12/15‐lipoxygenase (12/15‐LOX) inhibitor ML351 reduced tPA related HT in mice subjected to experimental stroke under anticoagulation. In this study,...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurochemistry Vol. 157; no. 3; pp. 586 - 598
Main Authors:	Cheng, Guangsen, Zhao, Wei, Xin, Yongjie, Huang, Guomin, Liu, Yongkang, Li, Zhongliang, Zhan, Meixiao, Li, Yong, Lu, Ligong, Leyen, Klaus, Liu, Yu
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01-05-2021
Subjects:	12/15‐lipoxygenase acute ischemic stroke Anticoagulants Blood flow Blood-brain barrier Cell activation Cerebral blood flow Combination therapy Cytokines Hemoglobin Hemorrhage hemorrhagic transformation IgG antibody Immunoglobulin G Immunohistochemistry Inflammation Ischemia JNK protein Kinases Lipoxygenase Liquid oxygen Macrophages Microglia ML351 Occlusion Proteins Reperfusion Stroke t-Plasminogen activator Therapy Thrombolysis tissue plasminogen activator ML351 tissue plasminogen activator hemorrhagic transformation acute ischemic stroke 12/15-lipoxygenase
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!